0000899243-20-018872.txt : 20200709 0000899243-20-018872.hdr.sgml : 20200709 20200709205029 ACCESSION NUMBER: 0000899243-20-018872 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200709 FILED AS OF DATE: 20200709 DATE AS OF CHANGE: 20200709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: George Simeon CENTRAL INDEX KEY: 0001595117 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39370 FILM NUMBER: 201021558 MAIL ADDRESS: STREET 1: 161 WASHINGTON STREET STREET 2: SUITE 500 CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nkarta, Inc. CENTRAL INDEX KEY: 0001787400 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474515206 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT STREET 2: SUITE 102 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-215-0385 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT STREET 2: SUITE 102 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-07-09 0 0001787400 Nkarta, Inc. NKTX 0001595117 George Simeon C/O S.R. ONE, LIMITED 161 WASHINGTON STREET, SUITE 500 CONSHOHOCKEN PA 19428 1 0 0 0 Series A Preferred Stock Common Stock 525499 I See Footnote Series B Preferred Stock Common Stock 1712810 I See Footnote The Series A Preferred Stock is convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. The Series B Preferred Stock is convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. Gives effect to the one-for-3.7 reverse stock split of the Issuer's common stock and a proportional adjustment to the conversion ratio of the Series A Preferred Stock and Series B Preferred Stock effective on July 1, 2020. S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Simeon J. George is the Chief Executive Officer, President and a Member of the Board of Trustees at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Exhibit List Exhibit 24 - Power of Attorney /s/ Matthew Plunkett Attorney-in-Fact for Simeon J. George 2020-07-09 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                   POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints each of Paul Hastings,
Chief Executive Officer of Nkarta, Inc., a Delaware corporation (the "Company"),
and Matthew Plunkett, Chief Financial Officer of the Company, the undersigned's
true and lawful attorney-in-fact to:

            1   execute for and on behalf of the undersigned, in the
                undersigned's capacity as an officer and/or director of the
                Company, Forms 3, 4, and 5 in accordance with Section 16(a) of
                the Securities Exchange Act of 1934, as amended and the rules
                thereunder (the "Exchange Act"), and/or authenticating documents
                pursuant to the rules governing the SEC's EDGAR Filer Management
                and application thereto;

            2   do and perform any and all acts for and on behalf of the
                undersigned which may be necessary or desirable to complete and
                execute any such Form 3, 4, or 5, complete and execute any
                amendment or amendments thereto, and timely file such form with
                the United States Securities and Exchange Commission and any
                stock exchange or similar authority; and

            3   take any other action of any type whatsoever in connection with
                the foregoing which, in the opinion of such attorney-in-fact,
                may be of benefit to, in the best interest of, or legally
                required by, the undersigned, it being understood that the
                documents executed by such attorney-in-fact on behalf of the
                undersigned pursuant to this Power of Attorney shall be in such
                form and shall contain such terms and conditions as such
                attorney-in-fact may approve in such attorney-in-fact's
                discretion.

        The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.

        The undersigned acknowledges that:

            1   neither the Company nor the foregoing attorney-in-fact assumes
                (i) any liability for the undersigned's responsibility to comply
                with the requirement of the Exchange Act, (ii) any liability of
                the undersigned for any failure to comply with such requirements
                or (iii) any obligation or liability of the undersigned for
                profit disgorgement under Section 16(b) of the Exchange Act; and

            2   this Power of Attorney does not relieve the undersigned from
                responsibility for compliance with the undersigned's obligations
                under the Exchange Act, including without limitation the
                reporting requirements under Section 16 of the Exchange Act.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company
unless earlier revoked by the undersigned in a signed writing delivered to each
attorney-in-fact.

                     [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 8th day of July, 2020.

                                        /s/ Simeon George
                                        ----------------------
                                        SIMEON GEORGE